THALOMID 150 MG
THALIDOMIDE : 150 MG · DIN 02355213 · CELGENE INC
Health Canada status: CANCELLED PRE MARKET
What is THALOMID?
THALOMID 150 MG contains THALIDOMIDE : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02355213, held by CELGENE INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled pre market, status dated 15-Apr-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is THALOMID used for?
THALOMID® (thalidomide capsules) in combination with melphalan and prednisone (MPT) is indicated for the treatment of patients with previously untreated multiple myeloma who are 65 years of age or older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02355213 |
|---|---|
| Brand name | THALOMID |
| Generic / active ingredient | THALIDOMIDE : 150 MG |
| Manufacturer | CELGENE INC |
| Strength | 150 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L04AX02 THALIDOMIDE |
| AHFS class | 92:20.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 15-Apr-2024 |
| Original market date | 2010-11-01 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
What can be used instead?
Other Canadian products sharing ATC code L04AX02 THALIDOMIDE. 2 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| THALOMID | 100 MG | CAPSULE | BRISTOL-MYERS SQUIBB CANADA | MARKETED | DIN 02355205 |
| THALOMID | 50 MG | CAPSULE | BRISTOL-MYERS SQUIBB CANADA | MARKETED | DIN 02355191 |
| THALOMID | 200 MG | CAPSULE | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | DIN 02355221 |
Who else supplies THALIDOMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. THALIDOMIDE appears in 10 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.